2026 Q2 Formulary Policy Updates
Please see the list of medications recently reviewed by the MVP Pharmacy and Therapeutics Committee.
Published April 2026
Please see the list of medications recently reviewed by the MVP Pharmacy and Therapeutics Committee. For coverage details, refer to the MVP Formularies available here. For more information about pharmacy changes, check the Provider FastFax Library or visit all policies here.
A list of formulary changes for Plan Year 2026 is available for review here. Changes will take effect on the Member’s pharmacy “Plan Year” start date.
Drugs removed from prior authorization for Commercial, Marketplace, and Self-Funded Formularies
- Ensacove
- Arbli
- Zelsuvmi
- Ibtrozi
- Averi
- Xifyrm
- Tryptyr
- Orlynvah
- Hernexeos
- Modeyso
New Drugs excluded for Commercial, Marketplace, and Self-Funded Formularies
- Merilog
- Leqselvi
- Anzupgo
- Brynovin
New generics that recently came to market
| Brand name | Generic name |
|---|---|
| Tracleer | Bosentan |
| Endometrin | Progesterone |
| Ravicti | Glycerol Phenbutyrate |
| Premarin | Conjugated estrogens |
| Gralise | Gabapentin ER |
| Lomustine | Gleostine |
| Cladribine | Mavenclad |
Policy Updates
Review other articles in this issue regarding formulary, pharmacy policy, and medical policy updates.